Completion of Patents to International Markets
STOCKHOLM, SE / ACCESSWIRE / October 13, 2021 / iZafe Group (STO:IZAFE-B)
iZafe Group AB (publ) ("iZafe" or "the Company") announces that they have filed for several completions of their PCT patent application. Thus, the Company enables a greater geographic patent protection, which is part of iZafe's strategy to strengthen and further develop its intangible assets internationally.
The scope of protection in question refers to the pharmaceutical robot Dosell and its services. The application has been submitted for protection in key markets that iZafe has identified and wherein iZafe has seen great demand for Dosell. These markets are Europe, the United States, Russia and China. The extensive geographic patent protection is sought in order to prepare for the international expansion that is planned to be executed after the ongoing rights issue.
"The pharmaceutical robot Dosell is perceived as simple and easy to use, both for the user and the caregiver, and this combined with an affordable price has led to us seeing a great potential internationally for both our corporate version and the consumer version. It is therefore crucial to work strategically with our intangible assets as we expand the business." says Anders Segerström, CEO of iZafe Group.
Furthermore, the Company has filed an international patent application regarding advanced, digitalized and smart functions that provide a more intelligent and adaptable version of Dosell.
By using sensors and other digital care equipment in the home and regularly measuring patient-specific data, the system provides even safer medication for patients. The international patent application enables iZafe to obtain patents in more than 150 countries. The current patent application creates a strong basis for patent protection in selected markets, including Sweden, the whole of Europe, Asia and the United States.
Anders Segerström, Chief Executive Officer
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm
iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.
The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: firstname.lastname@example.org . Further information is available at www.izafe.se/investor-relations/ .
SOURCE: iZafe Group
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
374Water, Inc.26.10.2021 19:12:48 CEST | Press release
374WATER EXPANDS INTO EUROPE Dr. Tali Harif Joins to lead EU Commercialization
Smart Eye26.10.2021 17:47:34 CEST | Press release
Smart Eye Enters into an Agreement to Acquire iMotions and Intends to Raise Equity in a Directed Share Issue
Silver Elephant Mining Corp.26.10.2021 14:55:15 CEST | Press release
Silver Elephant To Hold Special Meeting of Shareholders On December 14, 2021 To Approve Nickel and Vanadium Spin-outs
CoroWare, Inc.26.10.2021 14:32:23 CEST | Press release
CoroWare Subsidiary, CarbonMeta Research Ltd, Appoints Board of Director Members
BioInvent International25.10.2021 13:47:06 CEST | Press release
BioInvent Appoints Immunotherapy Expert Alexander Eggermont to Scientific Advisory Board
Promore Pharma25.10.2021 09:21:54 CEST | Press release
Promore Pharma Announces that Scientific Article has Been Published on Clinical Study Results with Ropocamptide for Venous Leg Ulcers
Smart Eye22.10.2021 08:51:53 CEST | Press release
Interim Report January - September 2021
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom